Last reviewed · How we verify
warfarine - low molecular heparin
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver, preventing blood clot formation.
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver, preventing blood clot formation. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment and prevention of deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | warfarine - low molecular heparin |
|---|---|
| Sponsor | University Hospital, Limoges |
| Drug class | Vitamin K antagonist |
| Target | Vitamin K epoxide reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Warfarin acts as an anticoagulant by inhibiting the gamma-carboxylation of vitamin K-dependent clotting factors, including prothrombin and factors VII, IX, and X. This inhibition prevents the formation of blood clots and reduces the risk of thromboembolic events. The exact mechanism of warfarin's action is complex and involves multiple pathways, including the inhibition of vitamin K epoxide reductase and the subsequent depletion of vitamin K-dependent clotting factors.
Approved indications
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis and pulmonary embolism
Common side effects
- Bleeding
- Nosebleeds
- Bruising
- Gastrointestinal bleeding
- Hemorrhagic stroke
Key clinical trials
- Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- warfarine - low molecular heparin CI brief — competitive landscape report
- warfarine - low molecular heparin updates RSS · CI watch RSS
- University Hospital, Limoges portfolio CI